ITCC-049 AFATINIB
Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology
Promotor Name : Boehringer Ingelheim
Investigator Name : B. GEOERGER
Trial registered on clinicaltrials.gov: NCT02372006
